• 
• Case-Based Modules
• Initial Evaluation
• Dermatologic Manifestations
• Oral Manifestations
• OIs: Prophylaxis
• OIs: Treatment
• Antiretroviral Rx
• Antiretroviral Rx: Resistance
• Antiretroviral Rx: Adverse Effects
• Drug-Drug Interactions
• Postexposure Prophylaxis
• Perinatal Transmission
• Special Populations
• Prevention for Positives
• Challenging Unknowns
• Resource-Limited Settings
• Interactive Tutorials
• Routine HIV Screening
• Oraquick Advance Rapid HIV Test
• HIV Integration
• This program is funded through Health Resources and Services Administration, US Department of Health and Human Services.

• Home
• About This Site
• Free CE
• AETC NRC
• Resources
• Feedback
• Site Map
• Authors

Opportunistic Infections: Prophylaxis

Question | Discussion | References | CME Credit

Case 2: Prophylaxis for Toxoplasma Encephalitis

You answered:

	The patient should receive prophylaxis for Toxoplasma encephalitis and the dapsone she takes for Pneumocystis prophylaxis will provide adequate prophylaxis against Toxoplasma encephalitis.

This answer is incorrect. The patient does need prophylaxis for Toxoplasma encephalitis, but dapsone alone is not sufficient prophylaxis.

Choose another answer:

	The patient's positive IgG antibody to Toxoplasma shows evidence of immunity to Toxoplasma and thus she does not need prophylaxis against Toxoplasma encephalitis.
	The patient should add atovaquone (Mepron) to the dapsone to provide adequate prophylaxis for both Pneumocystis pneumonia and Toxoplasma encephalitis.
	The patient should receive prophylaxis for Toxoplasma encephalitis. Dapsone alone does not provide sufficient protection against reactivation of Toxoplasma; she should take pyrimethamine in addition to dapsone.

[Back to Case 2 Question | Go to Correct Answer]

Disclaimer | Privacy Policy Copyright © 2004-2013 University of Washington